Lipids

, Volume 48, Issue 2, pp 127–137

Statin Treatment Improves Plasma Lipid Levels but not HDL Subclass Distribution in Patients Undergoing Percutaneous Coronary Intervention

  • Li Tian
  • Yucheng Chen
  • Chuanwei Li
  • Zhi Zeng
  • Yanhua Xu
  • Shiyin Long
  • Mingde Fu
Original Article

DOI: 10.1007/s11745-012-3750-6

Cite this article as:
Tian, L., Chen, Y., Li, C. et al. Lipids (2013) 48: 127. doi:10.1007/s11745-012-3750-6

Abstract

Despite the established efficacy of statin therapy, the risk of cardiovascular events remains high in many patients. We examined high-density lipoprotein (HDL) subclass distribution profiles among statin-treated coronary heart disease (CHD) patients undergoing percutaneous coronary intervention (PCI). Plasma HDL subclasses were measured in 85 patients with established CHD and quantified by two-dimensional gel electrophoresis and immunoblotting. In CHD patients with statin treatment, the mean value of total cholesterol (TC) reached the desirable level and the triacylglycerol level (TAG) was borderline high. Moreover, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoproteinA-I, and apolipoproteinB-100 levels in these patients resembled those in normolipidemic healthy subjects. The HDL subclass did not show a normal distribution and was characterized by the lower large-sized HDL2b contents and higher contents of small-sized preβ1-HDL in CHD patients, compared to those in normolipidemic control subjects. Multiple stepwise regression analysis revealed that the severity of coronary stenosis, determined by the Gensini Score, was significantly and independently predicted by HDL2b and HDL3b. Statin therapy was effective in modifying plasma lipids levels, but not adequate as a monotherapy to normalize the HDL subclass distribution phenotype of patients with CHD undergoing PCI. The HDL subclass distribution may aid in risk stratification, especially in patients with CHD and therapeutic LDL-C and HDL-C levels.

Keywords

Coronary heart diseaseHigh-density lipoprotein subclassesStatins therapyQuantitative coronary angiographyTwo-dimensional gel electrophoresis-immunodetection

Abbreviations

HDL

High density lipoprotein

CHD

Coronary heart disease

PCI

Percutaneous coronary intervention

QCA

Quantitative coronary angiography

TC

Total cholesterol

TAG

Triacylglycerol

LDL-C

Low density lipoprotein cholesterol

HDL-C

High density lipoprotein cholesterol

ApoA-I

ApolipoproteinA-I

ApoB-100

ApolipoproteinB-100

AMI

Acute myocardial infarction

SAP

Stable angina pectoris

UAP

Unstable angina pectoris

As

Atherosclerosis

LDL

Low density lipoprotein(s)

HDL

High-density lipoprotein(s)

RCT

Reverse cholesterol transport

HMG-CoA

3-Hydroxy3-methylglutaryl coenzyme A

ACC

American College of Cardiology

AHA

American Heart Association

TSH

Thyroid stimulating hormone

NCEP-ATPIII

National Cholesterol Education Program-Adult Treatment Panel III

BMI

Body mass index

PVDF

Polyvinylidene

BSA

Bovine serum albumin

HRP

Horseradish peroxidase

IgG

Immunoglobulin G

SRC

Standardized regression coefficient

ABCA1

ATP binding cassette transporter A1

VLDL

Very low density lipoprotein

SD

Standard deviation

Copyright information

© AOCS 2012

Authors and Affiliations

  • Li Tian
    • 1
    • 2
  • Yucheng Chen
    • 3
  • Chuanwei Li
    • 3
  • Zhi Zeng
    • 3
  • Yanhua Xu
    • 4
  • Shiyin Long
    • 5
  • Mingde Fu
    • 1
    • 2
  1. 1.Laboratory of Endocrinology and Metabolism, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  2. 2.State Key Laboratory of BiotherapySichuan UniversityChengduPeople’s Republic of China
  3. 3.Cardiovascular Department, West China HospitalSichuan UniversityChengduPeople’s Republic of China
  4. 4.Chengdu Hoist Biotechnology Co., Ltd.SichuanPeople’s Republic of China
  5. 5.Department of Biochemistry and Molecular BiologyUniversity of South ChinaHengyangPeople’s Republic of China